Global Vaccines Market, By Composition (Combination Vaccines, Monovaccines), Type (Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, Live-Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, DNA Vaccines), Kind (Routine Vaccine, Recommended Vaccine, Required Vaccine), Age of Administration (Pediatric Vaccine, Adult Vaccine), Diseases (Pneumococcal Disease, Measles, Mumps and Varicella, DPT, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis, Yellow Fever, Others), Route of Administration (Injectable, Oral, Nasal), End User (Community Hospitals, Hospitals, Specialty Centres, Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Vaccines Market Analysis and Size
As the number of reported COVID cases increased overall, people worldwide anticipated a vaccine capable of combating the virus. The vaccine market is expected to develop due to the rising demand for coronavirus vaccines. Governments and medical regulators accelerated vaccine development due to the epidemic's severity, even though normal vaccine development needed years to complete the necessary testing. According to the WHO, as of July 27, 2021, there were roughly 108 COVID-19 vaccines in the clinical development stage, 184 vaccines in the pre-clinical development stage, and 21 vaccines had already received approval.
Data Bridge Market Research analyses that the vaccines market, which is USD 67.57 billion in 2022, is expected to reach USD 152.39 billion by 2030, at a CAGR of 10.7% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Vaccines Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Composition (Combination Vaccines, Monovaccines), Type (Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, DNA Vaccines), Kind (Routine Vaccine, Recommended Vaccine, Required Vaccine), Age of Administration (Pediatric Vaccine, Adult Vaccine), Diseases (Pneumococcal Disease, Measles, Mumps and Varicella, DPT, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis, Yellow Fever, Others), Route of Administration (Injectable, Oral, Nasal), End User (Community Hospitals, Hospitals, Specialty Centres, Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Sanofi (France), Serum Institute of India Pvt. Ltd. (India), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Indian Immunologicals Ltd. (India), Novasep (France), MerckKGaA (Germany), Charles River Laboratories (U.K.), uniQure N.V. (Netherlands), Waisman Biomanufacturing (U.S.), Creative-Biogene (U.S.), Aldevron (U.S.), Addgene (U.S.), Oxford Biomedica (U.K.), Thermo Fisher Scientific (U.S), Fujifilm Corporation (Japan), Spark Therapeutics Inc. (U.S.)
Vaccine is a biological component that promotes the formation of antibodies against various infections already present in the body. It is typically created utilizing pathogens and chemical medications that serve as antigens to ward off sickness. Conjugate vaccines, inactivated vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines are the most common types in the market. They aid in the prevention of several serious illnesses, such as hepatitis, measles, polio, diphtheria, meningitis, influenza, tetanus, and rotavirus.
Vaccines Market Dynamics
- Several initiatives undertaken by organizations will propel the market growth
Organizations, governments, and vaccine producers have launched several programs to advance vaccine development and availability. Through the ACT Accelerator, the World Health Organization worked with researchers, companies, and international health organizations to accelerate the pandemic response. The United States government began Operation Warp Speed (OWS) in March 2020. OWS was tasked with creating and distributing 300 million COVID-19 vaccinations by January 2021. The World Health Organization (WHO) Access to COVID-19 Tools (ACT) Accelerator, led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the WHO, was launched in April 2020, and it includes the COVAX program, collaborating with vaccine producers to provide low-cost COVID-19 vaccines to countries.
- The rising use of vaccines will bolster the market growth
India's pharmaceutical market share was only $500 million in 2012, which was less than ideal. At the time, vaccine-preventable fatalities claimed approximately two million Indian lives annually, most of whom were children. India recognized a chance to improve business possibilities nationwide and make things right for its inhabitants. The Indian vaccine business saw substantial growth, reaching around $ 1.3 billion in 2019 because of increased vaccine development and outreach initiatives.
- Technological advancements in vaccine administration will act as an opportunity
Modern vaccination technologies are primarily motivated by the desire to hasten response times to new threats and make vaccines readily available for rapid deployment. The development of vaccines against challenging targets and the improvement of delivery technologies for maximal potency are also at the center of innovation in the vaccines sector. The creation of synthetic vaccine candidates, genetic analyses of disease progression and vaccine response, structure-based antigen design, and nanoparticle delivery methods are a few examples of vaccine delivery technology breakthroughs.
- Long timelines for vaccine manufacturing will hinder the growth of the vaccines market
Vaccine development is regarded as costly, complex, and time-consuming, frequently taking between 10 and 15 years due to the intricacy of production and accompanying procedures. Microbes, machinery, ambient factors, and culture procedures, results during manufacturing can vary greatly due to the countless combinations of biological components. The chemicals and techniques employed to track culture properties make the process more difficult and delay the manufacturing cycle.
This vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
- In 2021, GlaxoSmithKline plc announced that they submitted a Biologics License Application (BLA) to the USFDA for its experimental vaccination PRIORIX. Over 100 nations have recently granted licenses for the vaccine, initially registered in Germany.
- In 2020, GlaxoSmithKline plc and Medicago Inc., two of Mitsubishi Tanabe Pharma Corporation's subsidiary companies, announced their collaboration. They established a partnership to create a plant-based virus-like particle (VLP) vaccine for COVID-19.
Global Vaccines Market Scope
The vaccines market is segmented on the basis of composition, type, kind, age of administration, diseases, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Combination Vaccines
- Conjugate Vaccines
- Live-Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- DNA Vaccines
- Routine Vaccine
- Recommended Vaccine
- Required Vaccine
Age of Administration
- Pediatric Vaccine
- Adult Vaccine
- Pneumococcal Disease
- Japanese Encephalitis
- Yellow Fever
Route of Administration
- Community Hospitals
- Specialty Centres
- Hospital Pharmacy
- Retail Pharmacy
Vaccines Market Regional Analysis/Insights
The vaccines market is analysed and market size insights and trends are provided by country, composition, type, kind, age of administration, diseases, route of administration, end user and distribution channel as referenced above.
The countries covered in the vaccines market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the vaccine market due to several important businesses and sophisticated healthcare infrastructure. The development of new vaccines such as rotavirus, pneumococcal conjugate, and human papillomavirus vaccine promises new opportunities for cost reduction and establishing new supply chains and distribution logistics.
Asia-Pacific is expected to grow at the highest rate in the forecast period of 2023 to 2030 due to the growing patient population, rising healthcare industry investment, and expanding government assistance.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Vaccines Market Share Analysis
The vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to vaccines market.
Some of the major players operating in the vaccines market are:
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Sanofi (France)
- Serum Institute of India Pvt. Ltd. (India)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Indian Immunologicals Ltd. (India)
- Novasep (France)
- MerckKGaA (Germany)
- Charles River Laboratories (U.K.)
- uniQure N.V. (Netherlands)
- Waisman Biomanufacturing (U.S.)
- Creative-Biogene (U.S.)
- Aldevron (U.S.)
- Addgene (U.S.)
- Oxford Biomedica (U.K.)
- Thermo Fisher Scientific (U.S.)
- Fujifilm Corporation (Japan)
- Spark Therapeutics Inc. (U.S.)